Clinical Significance of National Institutes of Health-Chronic Prostatitis Symptom Index Pain Score in Patients with Benign Prostatic Hyperplasia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Many benign prostatic hyperplasia (BPH) patients were accompanied by pelvic pain apart from urinary symptoms. Therefore, we evaluate the treatment outcomes of alpha-blockers via a change of international prostate symptom score (IPSS) according to pain score of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI).Materials and Methods: A total of 356 male patients with BPH from March 2011 to May 2014 were analyzed retrospectively. Prostate specific antigen, prostate volume, IPSS, NIH-CPSI, international index of erectile function (IIEF-5), and uroflowmetry were collected. Patients were categorized according to 2 groups based on the presence and severity of pain and baseline characteristics and treatment outcomes were analyzed.Results: Two hundred twenty-nine patients (64.3%) reported pain/discomfort on NIH-CPSI. Mean IPSS, mean voiding symptoms, mean storage symptoms on IPSS, and mean IIEF-5 showed a significant difference in groups 1A and 1B. Logistic regression analysis showed that NIH-CPSI pain score was a significant predictive factor for severe IPSS (odds ratio, 2.830; 95% confidence interval, 1.307-6.129). After treatment for 3 months, improvement of IPSS, voiding symptoms, storage symptoms, and quality of life was observed in all groups (p=0.001, p<0.001, p=0.026, p<0.001, p<0.001, p<0.001, p<0.001, p<0.001). Group 2B (pain score>5) showed greater improvement of symptoms and statistically significant difference compared with group 2A (pain score ≤5) (p=0.029, p=0.026).Conclusions: We suggest that the presence and severity of pain score are helpful for therapeutic efficacy in patients with BPH.
Abstract
Purpose: Many benign prostatic hyperplasia (BPH) patients were accompanied by pelvic pain apart from urinary symptoms. Therefore, we evaluate the treatment outcomes of alpha-blockers via a change of international prostate symptom score (IPSS) according to pain score of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI).Materials and Methods: A total of 356 male patients with BPH from March 2011 to May 2014 were analyzed retrospectively. Prostate specific antigen, prostate volume, IPSS, NIH-CPSI, international index of erectile function (IIEF-5), and uroflowmetry were collected. Patients were categorized according to 2 groups based on the presence and severity of pain and baseline characteristics and treatment outcomes were analyzed.Results: Two hundred twenty-nine patients (64.3%) reported pain/discomfort on NIH-CPSI. Mean IPSS, mean voiding symptoms, mean storage symptoms on IPSS, and mean IIEF-5 showed a significant difference in groups 1A and 1B. Logistic regression analysis showed that NIH-CPSI pain score was a significant predictive factor for severe IPSS (odds ratio, 2.830; 95% confidence interval, 1.307-6.129). After treatment for 3 months, improvement of IPSS, voiding symptoms, storage symptoms, and quality of life was observed in all groups (p=0.001, p<0.001, p=0.026, p<0.001, p<0.001, p<0.001, p<0.001, p<0.001). Group 2B (pain score>5) showed greater improvement of symptoms and statistically significant difference compared with group 2A (pain score ≤5) (p=0.029, p=0.026).Conclusions: We suggest that the presence and severity of pain score are helpful for therapeutic efficacy in patients with BPH.
참고문헌 (27)
- Abrams P, "Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society", Neurourol Urodyn, 21, pp.167~178 (2002)
- Wei JT, "Urologic diseases in America project: benign prostatic hyperplasia", J Urol, 173, pp.1256~1261 (2005)
- Collins MM, "Prevalence and correlates of prostatitis in the health professionals follow-up study cohort", J Urol, 167, pp.1363~1366 (2002)
- Garraway WM, "High prevalence of benign prostatic hypertrophy in the community", Lancet, 338, pp.469~471 (1991)
- De Nunzio C, "The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation", Eur Urol, 60, pp.106~117 (2011)
- Briganti A, "Benign prostatic hyperplasia and its aetiologies", Eur Urol Suppl, 8, pp.865~871 (2009)
- Krieger JN, "Epidemiology of prostatitis", Int J Antimicrob Agents, 31(Suppl 1), pp.S85~S90 (2008)
- Vallancien G, "Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms", J Urol, 169, pp.2257~2261 (2003)
- Nickel JC, "Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial", J Urol, 178, pp.896~900 (2007)
- Nickel JC, "Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH", BJU Int, 95, pp.571~574 (2005)
- Braun MH, "Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey", Eur Urol, 44, pp.588~594 (2003)
- Rosen R, "Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)", Eur Urol, 44, pp.637~649 (2003)
- Collins MM, "How common is prostatitis? A national survey of physician visits", J Urol, 159, pp.1224~1228 (1998)
- Chung WS, "Lower urinary tract symptoms and sexual dysfunction in community-dwelling men", Mayo Clin Proc, 79, pp.745~749 (2004)
- Lepor H, "The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response", J Urol, 160, pp.1358~1367 (1998)
- Nickel JC, "Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study", CMAJ, 155, pp.1251~1259 (1996)
- McConnell JD, "The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia", N Engl J Med, 338, pp.557~563 (1998)
- Roehrborn CG, "Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia", Urology, 60, pp.434~441 (2002)
- Cheah PY, "Terazosin therapy for chronic prostatitis", chronic pelvic pain syndrome: a randomized, placebo controlled trial, 2003, pp.169, 592~596
- Mehik A, "Alfuzosin treatment for chronic prostatitis", chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study, 2003, pp.62, 425~429
- Nickel JC, "Treatment of chronic prostatitis", chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial, 2004, pp.171, 1594~1597
- 권영기, "The Effect of Intraprostatic Chronic Inflammation on Benign Prostatic Hyperplasia Treatment", Investigative and Clinical Urology, 51(4), pp.266~270 (2010), 대한비뇨기과학회
- Cantoro U, "Comparison of tamsulosin vs tamsulosin", sildenafil effectiveness in the treatment of erectile dysfunction in patients affected by type III chronic prostatitis, 2013, pp.85, 109~112
- Lacquaniti S, "Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo-controlled study", Arch Ital Urol Androl, 71, pp.283~285 (1999)
- de la Rosette JJ, "Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities", Eur Urol, 22, pp.222~227 (1992)
- Neal DE Jr, "Use of terazosin in prostatodynia and validation of a symptom score questionnaire", Urology, 43, pp.460~465 (1994)
- Ishigooka M, "Spinal substance P immunoreactivity is enhanced by acute chemical stimulation of the rat prostate", Urology, 59, pp.139~144 (2002)